Cost-Effectiveness Analysis of Lung Cancer Screening in the United States

医学 肺癌 癌症筛查 肺癌筛查 癌症 肿瘤科 重症监护医学 内科学
作者
Steven D. Criss,Harry J. de Koning,Sylvia K. Plevritis,Rafael Meza,Chung Yin Kong
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:172 (10): 706-707 被引量:6
标识
DOI:10.7326/l20-0072
摘要

Letters19 May 2020Cost-Effectiveness Analysis of Lung Cancer Screening in the United StatesSteven D. Criss, BS, Harry J. de Koning, MD, PhD, Sylvia K. Plevritis, PhD, Rafael Meza, PhD, and Chung Yin Kong, PhDSteven D. Criss, BSHarvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Search for more papers by this author, Harry J. de Koning, MD, PhDErasmus University Medical Center, Rotterdam, the Netherlands (H.J.D.)Search for more papers by this author, Sylvia K. Plevritis, PhDStanford University, Stanford, California (S.K.P.)Search for more papers by this author, Rafael Meza, PhDUniversity of Michigan, Ann Arbor, Michigan (R.M.)Search for more papers by this author, and Chung Yin Kong, PhDHarvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0072 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Young and Ms. Hopkins that the high prevalence of chronic obstructive pulmonary disease and other comorbidities among persons eligible for lung cancer screening limits the effectiveness of risk-based screening. The detection of lung cancer in patients who are ineligible for curative surgical treatment certainly attenuates the benefits of screening, as do the shorter life expectancy and higher rate of non–lung cancer deaths associated with comorbid disease. We also agree that it would be valuable for chronic obstructive pulmonary disease status to be part of conversations between patients and their physicians around the potential benefits ...References1. Chua GWY, Chua KLM. Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate. Thorac Cancer. 2019;10:1857-1867. [PMID: 31389163] doi:10.1111/1759-7714.13160 CrossrefMedlineGoogle Scholar2. Takeda A, Enomoto T, Sanuki N, et al. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest. 2013;143:130-137. [PMID: 22722234] doi:10.1378/chest.12-0207 CrossrefMedlineGoogle Scholar3. Warren GW, Alberg AJ, Kraft AS, et al. The 2014 Surgeon General's report: “The health consequences of smoking—50 years of progress”: a paradigm shift in cancer care [Editorial]. Cancer. 2014;120:1914-1916. [PMID: 24687615] doi:10.1002/cncr.28695 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Harvard Medical School and Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts (S.D.C., C.Y.K.)Erasmus University Medical Center, Rotterdam, the Netherlands (H.J.D.)Stanford University, Stanford, California (S.K.P.)University of Michigan, Ann Arbor, Michigan (R.M.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0322. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness Analysis of Lung Cancer Screening in the United States Steven D. Criss , Pianpian Cao , Mehrad Bastani , Kevin ten Haaf , Yufan Chen , Deirdre F. Sheehan , Erik F. Blom , Iakovos Toumazis , Jihyoun Jeon , Harry J. de Koning , Sylvia K. Plevritis , Rafael Meza , and Chung Yin Kong Cost-Effectiveness Analysis of Lung Cancer Screening in the United States Robert P. Young and Raewyn J. Hopkins Metrics Cited byBlood-Based Biomarker Panel for Personalized Lung Cancer Risk AssessmentContemporary issues in the implementation of lung cancer screening 19 May 2020Volume 172, Issue 10Page: 706-707KeywordsCancer screeningCancer treatmentChronic obstructive pulmonary diseaseDisclosureLife expectancyLung and intrathoracic tumorsLung cancer screeningRespiratory system proceduresSurgeryType 2 diabetes ePublished: 19 May 2020 Issue Published: 19 May 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开始完成签到,获得积分10
刚刚
刚刚
孙朱珠完成签到,获得积分10
1秒前
voyage完成签到,获得积分10
1秒前
molihuakai的应助被shc采纳,获得10
1秒前
one发布了新的文献求助10
1秒前
1秒前
阿巴阿巴完成签到,获得积分10
1秒前
zhdjk完成签到,获得积分10
2秒前
yzh完成签到,获得积分10
2秒前
酷酷念波发布了新的文献求助10
2秒前
2秒前
iv吃饭发布了新的文献求助10
2秒前
李健的小迷弟的应助被Liwanhe采纳,获得10
2秒前
3秒前
3秒前
3秒前
3秒前
Lgy发布了新的文献求助10
3秒前
4秒前
大模型的应助被moba采纳,获得10
4秒前
小鱼完成签到,获得积分10
5秒前
科研通AI6.4的应助被123采纳,获得10
5秒前
xiang发布了新的文献求助10
6秒前
CodeCraft的应助被可靠小馒头采纳,获得10
6秒前
6秒前
6秒前
Rose段发布了新的文献求助10
6秒前
小阿志发布了新的文献求助10
6秒前
6秒前
lalala完成签到,获得积分10
6秒前
辞仙发布了新的文献求助30
7秒前
7秒前
7秒前
春秋蚕发布了新的文献求助10
8秒前
岸然发布了新的文献求助10
9秒前
山口惠子发布了新的文献求助10
9秒前
虾乐完成签到,获得积分10
9秒前
萝卜头发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Représentation chimique de la structure des kérogènes et des asphaltènes en fonction de leur origine et de leur degré d'évolution 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Ecotourism 400
Comprehensive Heterocyclic Chemistry IV 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8060361
求助须知:如何正确求助?哪些是违规求助? 9484860
关于积分的说明 21328407
捐赠科研通 7628845
什么是DOI,文献DOI怎么找? 3395596
关于科研通互助平台的介绍 2526423
邀请新用户注册赠送积分活动 2434166